(MedPage Today) — HOUSTON — A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients with IgA nephropathy, interim findings from the phase III ORIGIN 3 trial found.
Among 203 participants…
Source link : https://www.medpagetoday.com/meetingcoverage/asn/118350
Author :
Publish date : 2025-11-06 20:15:00
Copyright for syndicated content belongs to the linked Source.
